key: cord-0780358-4xo38r2k
authors: Gupta, Nivedita; Rana, Salaj; Singh, Harpreet
title: Innovative point-of-care molecular diagnostic test for COVID-19 in India
date: 2020-11-04
journal: Lancet Microbe
DOI: 10.1016/s2666-5247(20)30164-6
sha: df6349aaeffa898551b8ca226c33a6dac4a858f5
doc_id: 780358
cord_uid: 4xo38r2k

nan

and also deployed for detection of Nipah virus disease (unpublished) and leptospirosis (unpublished), are now being used for detection of SARS-CoV-2. The Truelab workstation includes sample preparation, an RNA extraction system, an RT-PCR machine, and disposable kit components. The workstation is a chip-based, realtime quantitative PCR system that is portable, battery-operated, and fully automated, and weighs around 3 kg. This laboratory-in-a-suitcase can be used in remote areas and has network data transfer ability and an automated reporting system. Samples are collected in a viral lysis buffer with minimum biosafety and biosecurity requirements. Results from a single test are available in 45 mins. In addition, the quantitative PCR machine is available in three sizes: UnoDx, Duo, and Quattro, with capacity to test one, two, and four samples per run, respectively.

The Truenat Beta CoV E-gene screening assay and Truenat SARS-CoV-2 RdRp gene-confirmatory assay (Molbio Diagnostics, India) were earlier validated as a two-step test. 4 The assays were deployed for COVID-19 testing in various parts of India between April and June, 2020. 4 A multiplex assay combining E-gene screening and Orf1a-gene confirmatory assay has also been validated recently. 5 All three of these assays exhibited 100% sensitivity and specificity, and positive and negative predictive value when compared with the gold-standard RT-PCR test. A total of 2530 Truelab workstations are currently operational at 1008 sites in 530 districts of India. The figure in the appendix depicts the distribution of Truelab workstations in India. Of the total 70·7 million COVID-19 tests done in India up to Sept 25, 2020, 2·7 million (3·8%) have been run on Truelab workstations. This innovative technology-driven COVID-19 testing platform has been a game changer for testing in underserved areas and quick testing in emergency departments of health-care facilities in India.

The Central Tuberculosis Division of the Indian Ministry of Health and Family Welfare has procured the Truenat machines and provided cartridges for testing all over India. We are not paid by any pharmaceutical company or other agency to write this Correspondence. We declare no competing interests. 

Assessing a novel, lab-free, point-of-care test for SARS-CoV-2 (CovidNudge): a diagnostic accuracy study

SARS-CoV-2 (COVID-19) testing status

Rapid communication: molecular assays as initial tests for the diagnosis of tuberculosis and rifampicin resistance

Performance evaluation of Truenat TM Beta CoV and Truenat TM SARS-CoV-2 point of care assays for COVID-19

Performance evaluation of Truenat TM Covid-19 test on Truelab TM workstation

See Online for appendix